PCM
CYTK icon

Piermont Capital Management’s Cytokinetics CYTK Stock Holding History

Piermont Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-16,530
Closed -$119K – 244
2018
Q1 		$119K Sell
16,530
-2,600
-14% -$22.3K 0.04% 236
2017
Q4 		$156K Sell
19,130
-1,070
-5% -$12.1K 0.05% 236
2017
Q3 		$293K Sell
20,200
-20,218
-50% -$276K 0.1% 220
2017
Q2 		$489K Sell
40,418
-7,200
-15% -$100K 0.14% 229
2017
Q1 		$612K Buy
+47,618
New +$557K 0.15% 214

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Piermont Capital Management's CYTK Position: Q2 2018 in Review

Piermont Capital Management sold out of Cytokinetics (CYTK) in Q2 2018, closing a stake of 16,530 shares — an estimated $119K sold.

Piermont Capital Management first reported a position in CYTK in Q1 2017 and held it in 5 quarters. The position peaked at $612K in Q1 2017. 126 funds tracked by Wall St. Rank hold CYTK as of Q2 2018.

  • Piermont Capital Management reported no remaining Cytokinetics position as of Q2 2018 after selling out during the quarter.
  • Piermont Capital Management sold 16,530 Cytokinetics shares in Q2 2018, an estimated $119K.
  • Piermont Capital Management first reported a position in Cytokinetics in Q1 2017 and held it in 5 quarters.
  • Piermont Capital Management's Cytokinetics position peaked at $612K in Q1 2017.
  • 126 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2018.

Based on Piermont Capital Management's 13F filing for Q2 2018, filed 10 Aug 2018.